Trial Profile
Efficacy and safety of pemetrexed versus erlotinib in the second-line treatment of patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 13 Jan 2016 New trial record
- 01 Jan 2016 Results published in the Anticancer Research